ସ୍ତନ କ୍ୟାନ୍ସର
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
କେଉଁଠିକୁ ଯିବେ
ଏହି ଟ୍ରାଏଲ୍ ପାଇଁ ଭାରତର 10 ଟି ହସ୍ପିଟାଲ୍ ରୋଗୀ ନେଉଛନ୍ତି।
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Ca…
Sponsor: Pfizer
ClinicalTrials.gov ରେ NCT07062965
ରେଜିଷ୍ଟ୍ରିରେ ଶେଷ ଅପଡେଟ୍ 19 Oct 2026 · ଆମ ଦ୍ୱାରା 20 Oct 2026 ରେ ପଢାଯାଇଛି